Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Total Current Liabilities: 2010-2025

Historic Total Current Liabilities for Catalyst Pharmaceuticals (CPRX) over the last 13 years, with Sep 2025 value amounting to $128.7 million.

  • Catalyst Pharmaceuticals' Total Current Liabilities rose 22.15% to $128.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $128.7 million, marking a year-over-year increase of 22.15%. This contributed to the annual value of $120.7 million for FY2024, which is 58.66% up from last year.
  • As of Q3 2025, Catalyst Pharmaceuticals' Total Current Liabilities stood at $128.7 million, which was up 13.92% from $113.0 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' Total Current Liabilities' 5-year high stood at $128.7 million during Q3 2025, with a 5-year trough of $14.4 million in Q1 2021.
  • For the 3-year period, Catalyst Pharmaceuticals' Total Current Liabilities averaged around $90.4 million, with its median value being $92.3 million (2024).
  • Per our database at Business Quant, Catalyst Pharmaceuticals' Total Current Liabilities dropped by 20.16% in 2021 and then skyrocketed by 147.23% in 2023.
  • Over the past 5 years, Catalyst Pharmaceuticals' Total Current Liabilities (Quarterly) stood at $27.1 million in 2021, then skyrocketed by 112.79% to $57.6 million in 2022, then skyrocketed by 32.08% to $76.1 million in 2023, then skyrocketed by 58.66% to $120.7 million in 2024, then increased by 22.15% to $128.7 million in 2025.
  • Its last three reported values are $128.7 million in Q3 2025, $113.0 million for Q2 2025, and $111.6 million during Q1 2025.